Merck

Job as Manager Group Procurement in Merck Pharma

Merck Limited (formerly E. Merck Limited) was set up in India as the first Merck subsidiary in Asia in 1967. The Company operates both its Pharmaceuticals and Chemicals businesses in the country.
Merck was also the first Merck Group Company to go public in the year 1981.  The Merck Group now holds 51% of the share capital in Merck Limited, while the remaining 49% is traded on the Bombay Stock Exchange Ltd. and National Stock Exchange of India Ltd.  Merck Specialities Pvt. Ltd., the wholly owned Indian subsidiary of Merck KGaA, was incorporated in 2005.

Post: Manager Group Procurement

Merck announces increased quarterly Dividend

  • Posted on: 26 November 2015
  • By: Shalini.Sharma

Merck, known as MSD outside the United States and Canada, today announced that the Board of Directors has increased the company’s quarterly dividend to $0.46 per outstanding share of the company’s common stock, up $0.01 from $0.45 per outstanding share paid last quarter. Payment will be made on Jan. 8, 2016, to stockholders of record at the close of business on Dec. 15, 2015.

Lilly and Merck Expand Immuno-oncology Collaboration with Phase III Nonsquamous Non-Small Cell Lung Cancer Trial

  • Posted on: 24 November 2015
  • By: Shalini.Sharma

Eli Lilly and Company and Merck  known as MSD outside the United States and Canada, today announced the extension of an existing collaboration to evaluate the safety and efficacy of the combination of Lilly's ALIMTA® (pemetrexed for injection) and Merck's KEYTRUDA® (pembrolizumab) in a pivotal Phase III study in first-line nonsquamous non-small cell lung cancer (NSCLC). The study will be sponsored by Merck and will be open to patients with NSCLC in the first-line setting, regardless of PD-L1 status. Financial details of the collaboration were not disclosed.

FDA panel backs Merck & Co drug to reverse muscle relaxant effect

  • Posted on: 9 November 2015
  • By: Shalini.Sharma

Merck & Co's drug to reverse the effects of muscle relaxants used in surgery is safe and effective enough to warrant approval, an independent panel to the U.S. Food and Drug Administration said. The drug, which goes by the chemical name of sugammadex, has repeatedly been rejected by the FDA due to concerns about potentially dangerous allergic reactions, even though it is approved in more than 75 countries.

Merck's Glucophage(R) extended release (XR) can be used for more type 2 diabetes patients

  • Posted on: 7 November 2015
  • By: Shalini.Sharma

Merck a leading science and technology company, announced that the British Medicines and Healthcare products Regulatory Agency (MHRA), has approved on November 2 an updated labeling for Glucophage® XR (extended release metformin) for the treatment of patients with type 2 diabetes. The label change removes moderate renal impairment stage 3a and stable chronic heart failure from the list of the contraindications of Glucophage® XR.

Merck KGaA, Darmstadt, Germany, and Pfizer Announce Initiation of Phase III First-Line Trial of Avelumab in Patients with Recurrent or Stage IV Non-Small Cell Lung Cancer(NSCLC)

  • Posted on: 7 November 2015
  • By: Shalini.Sharma

Merck KGaA, Darmstadt, Germany, and Pfizer announced the initiation of an international Phase III study of the investigational cancer immunotherapy avelumab* in a treatment naïve advanced NSCLC setting. The study, JAVELIN Lung 100, is designed to assess the safety and efficacy of avelumab compared with platinum-based doublet chemotherapy, in patients with late-stage NSCLC who have not previously received any treatment for their systemic lung cancer. Avelumab (previously known as MSB0010718C) is an investigational fully human anti-PD-L1 IgG1 monoclonal antibody that potentially uses the body’s own immune system to fight cancer.

Pages